Muvalaplin an orally administered small molecule inhibitor designed to lower lipoprotein(a) [Lp(a)] levels.
Lp(a) is a known cardiovascular risk factor associated with atherosclerotic disease and aortic stenosis.
It works by inhibiting the formation of Lp(a) through the disruption of the interaction between apolipoprotein(a) [apo(a)] and apolipoprotein B100 (apo B100), without affecting plasminogen, a homologous protein.
It targets the assembly of the lipoprotein (a) particle rather than apolipoprotein expression.
It is well tolerated and effective in reducing Lp(a) levels.
Muvalaplin was shown to lower Lp(a) levels by up to 65% with daily administration over 14 days:with reductions up to 85.8% at higher dosages over a 12-week period.